Dr Ann Childress, President of the Center for Psychiatry & Behavioral Medicine & CTx-1301 principal investigator identifies the difficult times of the day for controlling #ADHD.
$CING #Cingulate #Biotech #LifeSciences #FDA
youtu.be/RY8tVzRxxuI

🐶✨ Did you catch the puppies yet?!

Swing by the Discovery Hall today until 1:30 PM for some puppy love and a little mid-day joy.

Trust us… you don’t want to miss this. 🐾💕

#ADHD2025 #PuppyBreak #ConferenceJoy #Cingulate #ADHDFamily #puppiesofbluesky

Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control Once-daily formulation of dexmethylphenidate achieved primary endpoint (p < 0.001) with consistent symptom relief up to 12 hours post-doseKANSAS CITY, Kan., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cingulate...

#Cingulate presented Ph3 data @aacap.bsky.social. The study's CTx-1301 met its primary endpoint.
$CING
finance.yahoo.com/news/cingula...
See Dr Childress interview here:
youtu.be/dqtecwuIh40

Dr Ann Childress, principal investigator on #Cingulate CTx-1301 trials, comments on an article that finds an association between use of ADHD medication and lower suicide risk.
$CING
www.bmj.com/content/390/...
#ADHD #Biotech #DrugDevelopment #ADHDTreatment #NASDAQ

Dr. Ann Childress, principal investigator on Cingulate's CTx-1301 trials, shares a story about ADHD medications that only work for part of the day.
$CING
#Cingulate #ADHD #Neuroscience #Biotech #BiotechStocks #LifeSciences #NASDAQ

Dr. Ann Childress describes how the new #ADHD medication CTx-1301 works in this brief clip.
$CING
#Cingulate #Biotech #ClinicalTrials #LifeSciences #ADHDResearch #BiotechInvesting #PharmaNews #NASDAQ